Pharming Group (NASDAQ:PHAR) Trading Down 3.6% – What’s Next?

Pharming Group (NASDAQ:PHAR) traded down 3.6% during trading on Monday . The company traded as low as $8.80 and last traded at $8.63. 2,744 shares changed hands during trading, a decline of 56% from the average session volume of 6,183 shares. The stock had previously closed at $8.95.

Analyst Ratings Changes

PHAR has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Friday. Oppenheimer increased their price target on Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective on the stock.

Pharming Group Trading Down 3.4 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The stock has a market cap of $588.47 million, a P/E ratio of -33.27 and a beta of -0.10. The stock’s 50-day moving average is $8.99 and its two-hundred day moving average is $8.59.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The firm had revenue of $92.70 million for the quarter, compared to analysts’ expectations of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts anticipate that Pharming Group will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.